I think this is a very important slide from the last trial results presentation, showing that control patients who received dexamethasone showed no survival benefit. But once treated with Remestemcel-L + dexamethasone, a significant survival benefit of 75% at day 60 and 77% at day 90 was observed (in patients<65).
No treatment for ARDS has ever shown such a significant mortality reduction in any patient population. These are the sickest Covid-19 patients who are in ICU on mechanical ventilation who now have an 86% chance of survival compared to just 55% with current SOC.
Ann: Appendix 4C Quarterly Activity Report, page-216
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |